Effectiveness of Submucosal Dexamethasone Versus Methylprednisolone in Reducing Postoperative Symptoms After Mandibular Parasymphysis Fracture Surgery

What this Trial Is About

Researchers are evaluating the effects of two corticosteroids, dexamethasone and methylprednisolone, on reducing postoperative pain, swelling, and limited mouth opening trismus in patients with isolated mandibular parasymphysis fractures. This clinical trial addresses the current uncertainty about which steroid is more effective for managing these postoperative complications. The study aims to provide clear evidence to guide clinicians in choosing the best steroid treatment to improve patient recovery after surgery. The trial compares two groups one receiving a single submucosal dose of dexamethasone 8 mg and the other receiving a single submucosal dose of methylprednisolone 40 mg. Both drugs are administered at the surgical site 30 minutes before the incision during open reduction and internal fixation surgery. The study uses a double-blind, randomized design to fairly assess the outcomes of both treatments. Participants will be monitored for facial swelling and pain intensity at baseline, 24 hours, and 72 hours after surgery. Blood samples will be taken to measure serum C-reactive protein, an objective marker of inflammation, at the same time points. Researchers will also track the use of additional pain medication and any side effects. This thorough assessment combining clinical signs and lab tests will help determine which steroid provides better postoperative control of symptoms. The study will continue until late 2026, ensuring comprehensive follow-up.

Comparison of Submucosal Dexamethasone and Methylprednisolone in Postoperative Sequelae of Parasymphsis Fractures